Overview

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

Status:
Unknown status

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

This is a single arm phase II clinical trial, which aims to evaluate the effectiveness of combination of gefitinib and doublet chemotherapy or antiangiogenesis in advanced non-small cell lung cancer patients with EGFR activating mutation, accompanied with Bim deletion or low activating EGFR mutation abundance.

Phase:

Phase 2

Details

Lead Sponsor:

Caicun Zhou

Treatments:

Bevacizumab
Carboplatin
Gefitinib
Gemcitabine
Pemetrexed